Chronic idiopathic constipation in adults: epidemiology, pathophysiology, diagnosis and clinical management

Christopher J Black, Alexander C Ford

Chronic idiopathic constipation (CIC) is one of the most common gastrointestinal disorders worldwide.1 It can be divided into three subtypes: dyssynergic defaecation (DD), which is a problem with rectal evacuation; slow transit constipation; and normal transit constipation, which is the most common subtype.2 This Narrative Review examines the epidemiology, pathophysiology and clinical management of CIC in adults. It is based on a synthesis of relevant evidence from articles listed in PubMed from inception until January 2018, including original research articles, consensus guidelines and opinion articles.

Definition

Patients with CIC usually present with symptoms including hard or lumpy stools, reduced frequency of defaecation, a sensation of incomplete evacuation or blockage, straining at stool, and some may also report abdominal pain and bloating.3 In general, symptoms are deemed to be chronic if they have been present for at least 3 months.

The Bristol Stool Form Scale (BSFS) (Box 1) is a validated tool that describes the different consistencies of stool a patient may experience.3 Stool types 1 and 2 are indicative of hard stools, and types 6 and 7 are loose or watery stools. The stool consistency has been shown to correlate well with colonic transit time,5,6 whereas the overall frequency of defaecation may not,6,7 although the majority of patients presenting with CIC have normal colonic transit.8 This is also referred to as functional constipation and is defined by the Rome IV diagnostic criteria (Box 2). In practice, these criteria can be difficult to apply and, because abdominal pain is so often reported in functional constipation, it can be difficult to distinguish functional constipation from irritable bowel syndrome with constipation (IBS-C).9,10

Epidemiology

A previous meta-analysis across 45 population-based studies showed a pooled global prevalence of CIC of 14%, with little variation by geographical region, although data from the Middle East, Central America and Africa were scant.11 It has traditionally been held that the prevalence of CIC increases with age, with higher rates reported in older people,12 a trend that was confirmed, albeit modestly, by this meta-analysis.11 Regarding gender, most chronic gastrointestinal disorders, including IBS, are more common in women,13 and the same is true of CIC. The meta-analysis indicated that the prevalence of CIC among women was almost twice that in men.11 Finally, low socio-economic status has been identified as a risk factor for CIC.14 There was a modest increase in the prevalence of CIC among patients of lower compared with higher socio-economic status, but not when comparing medium with higher socio-economic status.11

Summary

- Chronic idiopathic constipation is one of the most common gastrointestinal disorders, with a global prevalence of 14%. It is commoner in women and its prevalence increases with age.
- There are three subtypes of CIC: dyssynergic defaecation, slow transit constipation and normal transit constipation, which is the most common subtype.
- Clinical assessment of the patient with constipation requires careful history taking, in order to identify any red flag symptoms that would necessitate further investigation with colonoscopy to exclude colorectal malignancy.
- Screening for hypercalcaemia, hypothyroidism and coeliac disease with appropriate blood tests should be considered.
- A digital rectal examination should be performed to assess for evidence of dyssynergic defaecation. If this is suspected, further investigation with high resolution anorectal manometry should be undertaken.
- Anorectal biofeedback can be offered to patients with dyssynergic defaecation as a means of correcting the associated impairment of pelvic floor, abdominal wall and rectal functioning.
- Lifestyle modifications, such as increasing dietary fibre, are the first step in managing other causes of CIC. If patients do not respond to these simple changes, then treatment with osmotic and stimulant laxatives should be trialled.
- Patients not responding to traditional laxatives should be offered treatment with prosecretory agents such as lubiprostone, linaclotide and plecanatide, or the 5-HT4 receptor agonist prucalopride, where available.
- If there is no response to pharmacological treatment, surgical intervention can be considered, but it is only suitable for a carefully selected subset of patients with proven slow transit constipation.

Normal colonic physiology

To understand the investigation and treatment of CIC, it is helpful to briefly consider the normal physiological functioning of the colon.

Motility

Although peristalsis is observed in the colon, the main mechanism of propulsive motility is via mass movements, which occur a few times each day, ultimately leading to defaecation.15 They arise from the inhibition of distal haustral segments and contractions of the proximal bowel wall. The primary motor pattern associated with these mass movements is called a high amplitude propagating contraction,16 which arises from the contraction of colonic smooth muscle, although the underlying neurophysiological mechanism remains incompletely understood.

Peristalsis, on the other hand, is predominantly mediated by serotonin, or 5-hydroxytryptamine (5-HT), which is synthesised and released by enterochromaffin cells.17 Serotonin activates receptors,
which send signals via the myenteric nerve plexus, propagating a wave of intestinal smooth muscle contraction and propelling luminal contents. The interstitial cells of Cajal act as a pacemaker, mediating between the signals of the enteric nervous system and intestinal smooth muscle.\(^\text{16}\)

Colonic contents can also move in a retrograde direction, which is more marked after a meal and potentially provides a “brake” to prevent rapid rectal filling.\(^\text{19}\) At the same time, there is also a general postprandial increase in colonic motor activity — the so-called gastrocolic reflex.

**Fluid and electrolytes**

The colon has an important role in managing intestinal fluid and electrolyte content, and reabsorbs about 1–2 L of fluid per day.\(^\text{20}\) Prosecretory drugs can increase intestinal luminal fluid and electrolyte content sufficiently to saturate this process, thereby altering stool consistency and reducing colonic transit time.\(^\text{21}\) Alternatively, osmotic laxatives increase luminal water content by creating an osmotic gradient across the intestinal epithelium, with similar effects.\(^\text{22}\)

**Pathophysiology**

### Normal transit (functional) constipation

Despite normal transit constipation being the most prevalent subgroup of CIC, the pathophysiology remains unclear.\(^\text{27}\) Changes in the colonic microbiota can increase bile acid metabolism,\(^\text{24}\) promote methane production\(^\text{25}\) and affect epithelial function, all of which can alter colonic motility and fluid secretion, resulting in constipation.\(^\text{26}\)

As with other functional gastrointestinal disorders, there are also dietary and other lifestyle, behavioural and psychological factors that may be involved in the aetiology of symptoms.\(^\text{27-29}\)

### Rectal evacuation disorders

These constitute the second most common cause of CIC. Emptying the rectum requires coordination of the rectal and abdominal wall muscles, the anal sphincters and the pelvic floor muscles. DD, which is the most common disorder of rectal evacuation, arises when this coordination is impaired in some way, leading to paradoxical anal contraction, failure or impairment of anal relaxation, or inadequate rectal and abdominal propulsive force.\(^\text{30}\)

Slower colonic transit is often present concurrently.\(^\text{31}\)

DD is an acquired and learned behavioural problem, often resulting from dysfunctional toilet habits. In one study, sexual abuse was reported in 22% of cases, and physical abuse in 32%,\(^\text{32}\) and there was a significant impact on health-related quality of life. Problems with rectal evacuation can coexist with a structural cause, such as a rectocele, rectal prolapse or rectal intussusception.\(^\text{33}\)

### Slow transit constipation

Among patients with slow transit constipation, which is the least prevalent subtype of CIC, there may be a limited, or absent, increase in postprandial motor activity,\(^\text{34}\) and normal retrograde colonic propulsion may also be impaired.\(^\text{35}\) These patients may exhibit delayed emptying of the proximal colon,\(^\text{36,37}\) and either a reduction or complete absence of high amplitude propagating contractions.\(^\text{35,37,38}\) Mediation of peristalsis via 5-HT can also be impaired.\(^\text{16}\)

Moreover, individuals with severe slow transit constipation can exhibit abnormal or reduced numbers of interstitial cells of Cajal.\(^\text{39,40}\)

### Clinical assessment and investigation

A thorough history is the most important element in the clinical assessment of the patient with constipation. The physician must be vigilant for the presence of red flag symptoms, such as weight loss or rectal bleeding, which should prompt urgent investigation with colonoscopy or cross-sectional imaging as appropriate, primarily to exclude colorectal or other intra-abdominal malignancy (Box 3). Otherwise, colonoscopy is not a useful investigation for constipation in general. Any association between chronic constipation and the development of colorectal cancer is controversial; a 2013 meta-analysis argues against such a link.\(^\text{41}\)

Enquiring about the patient’s medical history is important. Constipation can arise secondary to neurological conditions, such as Parkinson disease and multiple sclerosis; endocrine disorders, such as hypothyroidism and hypercalcaemia; and prescribed medications, such as opiates or tricyclic antidepressants. Blood tests for thyroid function and calcium should be considered, as well as testing for coeliac disease. Although more commonly associated with symptoms of diarrhoea, weight loss and abdominal pain, coeliac disease was associated with constipation in 10% of patients in a large cohort study.\(^\text{32}\)

An obstetric and gynaecological history is also important when assessing symptoms of constipation in women.\(^\text{43}\) One study noted that the odds of obstructive defaecation increased twofold in women who had undergone vaginal or laparoscopic hysterectomy,\(^\text{44}\) and vaginal delivery and higher parity have both been shown to increase the risk of defaecatory symptoms arising from pelvic floor dysfunction.\(^\text{45}\)

---

**The Bristol Stool Form Scale**

<table>
<thead>
<tr>
<th>Type 1</th>
<th>Separate hard lumps</th>
<th>SEVERE CONSTIPATION</th>
</tr>
</thead>
<tbody>
<tr>
<td>Type 2</td>
<td>Lumpy and sausage like</td>
<td>MILD CONSTIPATION</td>
</tr>
<tr>
<td>Type 3</td>
<td>A sausage shape with cracks in the surface</td>
<td>NORMAL</td>
</tr>
<tr>
<td>Type 4</td>
<td>Like a smooth, soft sausage or snake</td>
<td>LACKING FIBRE</td>
</tr>
<tr>
<td>Type 5</td>
<td>Soft blobs with clear-cut edges</td>
<td>MILD DIARRHEA</td>
</tr>
<tr>
<td>Type 6</td>
<td>Mucous consistency with ragged edges</td>
<td>SEVERE DIARRHEA</td>
</tr>
</tbody>
</table>

Digital rectal examination has been shown to be reliable for identifying DD in patients who have chronic constipation, with a sensitivity and specificity of 75% and 87% respectively. The presence of two of the following features is required: impaired perianal descent, paradoxical anal contraction or impaired push effort. If DD is suspected, based on digital rectal examination, physiological testing with high resolution anorectal manometry may be useful to confirm the diagnosis.

High resolution manometry enables measurement of both anal resting and squeeze pressures and the rectal pressure during simulated defaecation, and can therefore help in identifying DD. However, many manometry patterns that were once considered abnormal have been observed in healthy asymptomatic individuals, which may limit utility. It is important to correlate the result with patient symptoms, and careful clinical judgement must be exercised. Defaecation proctography, traditionally using fluoroscopy and, more recently, magnetic resonance imaging, can elucidate obstructive causes of defaecation, such as rectal intussusception or rectocele.

The standard means of assessing colonic transit is the radio-opaque marker test, which is relatively simple and widely available. A capsule containing 20 radio-opaque markers is swallowed by the patient and a plain abdominal x-ray is taken 5 days later. Retention of five or more markers is indicative of slow transit, but care must be taken not to overinterpret the result, with a recent study showing that the number of retained markers does not correlate with symptom severity or quality of life in CIC.

Colonic transit can also be measured using other modalities, including colonic scintigraphy, where patients are given a radiolabelled meal and timed measurements of residual radioactivity are made to calculate transit, and wireless motility capsule, which uses changes in pH along the gastrointestinal tract to determine transit time. In practice, these investigations are used in a limited number of specialist centres, and are not routine in investigating patients with constipation.

### Management

#### Lifestyle

Modification of lifestyle factors, including diet, hydration and exercise, is usually the first step in managing CIC (Box 3).

**Diet.** Patients with CIC are often told to increase their dietary fibre intake, with guidelines suggesting 25–30 g of fibre per day. This should be introduced slowly, with gradual titration to avoid side effects. Insoluble fibres, such as wheat bran, may accelerate gastrointestinal transit, thereby increasing stool frequency. However, negative effects have been reported, particularly in patients with IBS-C, for whom insoluble fibre may worsen symptoms, including abdominal pain and bloating. Soluble fibre such as psyllium, derived from ground ispaghula husk, when ingested with water increases stool frequency. Sterculia may be an alternative in those who experience side effects with psyllium.

A systematic review by Suárez and Ford, which included six randomised controlled trials (RCTs) of soluble and insoluble fibre, found evidence of limited benefit overall in CIC, but suggested that soluble fibre was more effective than placebo, and led to improvements in individual symptoms. A further systematic review with meta-analysis by Christodoulides and colleagues also suggested that soluble fibre was effective for treating CIC, but highlighted that it may also cause unwanted gastrointestinal side effects, such as increased flatulence. Overall, the quality of evidence was low and the findings should be interpreted cautiously, due to a high risk of bias among all included studies. Both these systematic reviews identified a need for further large studies of fibre for the treatment of CIC.

**Probiotics.** Whether probiotics have a role in CIC is unclear. There is some suggestion they might improve gut transit time, stool frequency and stool consistency. However, more rigorous RCTs are needed to overcome the potential biases that blight the currently available studies.

**Hydration.** There is no evidence that CIC can be successfully treated by increasing fluid intake, unless there is evidence of dehydration. In the only study to date of increased fluid intake alone, 117 adult patients, for whom constipation was defined as fewer than three bowel movements per week, were randomly allocated to either unrestricted fluid intake or 2 L of mineral water daily, over a 2-month period. Stool frequency increased by 1.3 stools per week...
in the control group and 2.4 stools per week in the intervention group. However, the results are unreliable, as baseline data were assessed by patient recall and the mineral water contained magnesium, which could have exerted a laxative effect. Another study examined the effects of adding extra water to ingested wheat bran, but found no beneficial effect on stool frequency or form.62

Exercise. A study in patients with IBS found that increased physical activity improved gastrointestinal symptoms and was also protective against a deterioration in symptoms,63 effects which might be mediated through positive effects on anti-inflammatory and anti-oxidant pathways, as well as immune function.64 In CIC specifically, although intervention programs to increase physical activity may be of some help in older patients,62 there is no evidence to suggest that increasing levels of physical activity in younger people is beneficial.23

Pharmacological treatments
Medications for treating constipation principally include osmotic or stimulant laxatives, prosecretory drugs and 5-HT4 receptor agonists.

Osmotic laxatives. If patients fail to respond to lifestyle measures, osmotic laxatives such as polyethylene glycol and lactulose are the first-line drug treatment. A meta-analysis that included six RCTs comparing osmotic laxatives with placebo for treating CIC found that, overall, osmotic laxatives were more effective, with a number needed to treat of three.65 In individual RCTs, polyethylene glycol appeared to be superior to both lactulose66 and prucalopride, a 5-HT4 receptor agonist,67 when compared directly. Lactulose may also be poorly tolerated, as it frequently causes bloating.

Stimulant laxatives. Stimulant laxatives may be used if there is no response to osmotic laxatives. Bisacodyl and sodium picosulphate are both well tolerated and improve bowel function, symptoms and quality of life in RCTs.68,69 Interestingly, a systematic review and network meta-analysis found bisacodyl to be superior not only to sodium picosulphate but also to prosecretory drugs and 5-HT4 receptor agonists.70 Senna, an anthraquinone laxative, is frequently prescribed in CIC, but to date there are no placebo-controlled trials assessing its efficacy. Bisacodyl can also be given as an enema. Although other stimulants given per rectum, such as glycerol suppositories or phosphate or sodium citrate enemas, may provide individual patients with more predictability and control over their bowel habits, there are no RCTs to support their efficacy.71 There is no evidence to suggest that patients become dependent on stimulant laxatives.72

Prosecretory agents. If a patient fails to respond to conventional laxatives, prosecretory drugs may be tried. Lubiprostone, linaclotide, and plecanatide all work by increasing fluid and electrolyte flux into the intestinal lumen, although, at the time of writing, none of these drugs were available in Australia. Lubiprostone achieves this by activating chloride 2 channels on the luminal epithelial cells, whereas linaclotide and plecanatide activate the cystic fibrosis transmembrane conductance regulator (CFTR) chloride channel by increasing luminal cyclic guanosine monophosphate. A meta-analysis by Li and colleagues summarising data from nine RCTs of lubiprostone versus placebo in CIC and IBS-C, found significant improvements in severity of constipation, stool consistency and degree of straining after one month, but there was no longer a significant difference between groups by 3 months.73 Side effects, particularly nausea, are commoner with lubiprostone.74

Treatment of CIC with 12 weeks of linaclotide was found to significantly reduce bowel and abdominal symptoms when compared with placebo in two RCTs.75 Patients treated with linaclotide were also significantly more likely to reach the primary endpoint of three or more spontaneous bowel movements per week. Diarrhoea was the most frequent side effect experienced by those taking linaclotide, resulting in discontinuation of the drug in 4% of patients.

In RCTs of plecanatide for treating CIC,76,77 the drug improved constipation-related symptoms, when compared with placebo, over 12 weeks, but diarrhoea was again the predominant side effect. Patients taking plecanatide had significantly more spontaneous bowel movements per week, as well as significant improvements in stool consistency.

5-HT4 receptor agonists. Prucalopride is a selective 5-HT4 receptor agonist which stimulates gastrointestinal and colonic motility. An integrated analysis of six phase 3 and 4 RCTs showed that significantly more patients with CIC achieved a mean of three or more spontaneous bowel movements per week with treatment with prucalopride 2 mg once daily for 12 weeks compared with placebo.78 Overall, the drug was well tolerated; common side effects included diarrhoea and headache. The dose should be reduced to 1 mg once daily in older patients or those with renal or hepatic impairment.

Emerging drug treatments. Drug development continues with new treatments for CIC on the horizon. Like prucalopride, velu-setrag and naronapride are both selective 5-HT4 receptor agonists with prokinetic effects.79,80 These drugs have shown some promise in phase 2 clinical trials, but are yet to be evaluated any further.

Elobixibat, which is currently being evaluated in two large phase 3 RCTs, is an inhibitor of the ileal bile acid transporter, which effectively induces a state of bile acid malabsorption, resulting in increased colonic motility and fluid secretion.81 It may be a valuable new pharmacological therapy for CIC.

Other treatments
Anorectal biofeedback
Anorectal biofeedback, which is a behavioural training technique, can be used in the treatment of DD. It comprises measurement of anorectal physiology, with the abnormal responses shown to the patient in real time and targeted training to correct them, thus improving anorectal function. It employs a combination of techniques, which can include training to improve abdominal straining and push effort, training to relax the pelvic floor during defaecation, the simulation of defaecation by expulsion of a balloon from the rectum, and sensory retraining when rectal sensation is impaired.82 It has been shown to be effective in RCTs when compared with both standard treatment for CIC and sham therapies.83 However, a Cochrane review reported that the quality of evidence for use of biofeedback was poor overall and recommended that larger RCTs were conducted.

Transanal irrigation
Transanal irrigation is a commonly used treatment for disordered defaecation. In adults, this is predominantly in the context of neurogenic bowel, for which it is reimbursable in Australia, rather than CIC.84 It is a generally safe intervention and can be considered for treating CIC in adults when pharmacological treatments have proved to be ineffective and, particularly, before irreversible surgical procedures are considered.85 However, a recent study revealed that although it can lead to significant improvements in bowel function and quality of life among patients with CIC at 12 months, more than one-third of patients discontinue it within the first year, largely due to an unsatisfactory effect.86
Surgery

Surgical procedures include total colectomy with either ileorectal anastomosis or ileostomy formation. However, they are rarely indicated, and strict patient selection criteria are vital. Surgery is only suitable for patients with proven slow transit, for whom other correctible causes of constipation have been excluded, and who have failed to respond to all available pharmacological treatments. This patient group may benefit from total colectomy with ileorectal anastomosis. Outcomes can be very good when strict selection criteria are applied, with high levels of patient satisfaction and improvements in quality of life reported.

Surgery is not suitable for patients with IBS-C, or for those with pure DD. When slow transit constipation and DD coexist, DD should be corrected before surgery. If this is not achievable, then formation of an ileostomy is the only suitable surgical intervention.

Conclusion

CIC is a very common disorder. In the past 15 years, patients have benefitted from an expansion in treatment options, beyond simple dietary manipulation and the use of conventional laxatives. Further research in CIC should focus on understanding the neuropathophysiology responsible for normal transit constipation, including additional exploration of the role of both the microbiome and probiotics in CIC. Larger RCTs investigating biofeedback for treating DD are needed, in conjunction with improving access to biofeedback for patients, as well as larger trials of dietary fibre. We need to better understand which investigations assess colonic physiology most accurately in clinical practice, how to make them more acceptable to patients, as well as more representative of real life; for example, assessing defaecatory function with the patient sitting instead of lying down, as is currently the case. Finally, head-to-head comparisons of the efficacy of existing prosecretory drugs for treating CIC are required, and the results of further trials of drugs in development are also awaited.

Competing interests: No relevant disclosures.

Provenance: Commissioned; externally peer reviewed.

© 2018 AMPCo Pty Ltd. Produced with Elsevier B.V. All rights reserved.

References

9. Whitehead WE, Palsson OS, Simren M. Biomarkers to fitted from an expansion in treatment options, beyond high resolution, abnormalities in slow transit constipation de.
11. Suárez NC, Ford AC. Prevalence of, and risk factors for, chronic idiopathic constipation in the community: Systematic review and meta-analysis. Am J Gastroenterol 2011; 106: 1582-1591; quiz 1, 92.